Form 8-K - Current report:
SEC Accession No. 0001628280-22-002106
Filing Date
2022-02-09
Accepted
2022-02-09 16:10:57
Documents
13
Period of Report
2022-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20220209.htm   iXBRL 8-K 45692
2 EX-10.1 ex101amendment3toloanandse.htm EX-10.1 99162
  Complete submission text file 0001628280-22-002106.txt   305804

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20220209.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20220209_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20220209_pre.xml EX-101.PRE 13731
7 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20220209_htm.xml XML 11887
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22607323
SIC: 2836 Biological Products, (No Diagnostic Substances)